Stoke Therapeutics, Inc.
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $217.8M | $144.9M |
| FY2022 | — | $184.8M | $113.6M |
| FY2023 | — | $159.6M | $191.4M |
| FY2024 | — | $229.0M | $128.0M |
| FY2025 | — | $352.5M | $84.2M |
Equity & Debt
| Fiscal Year | Long Term Debt | Share Holder Equity | Cash on Hand |
|---|---|---|---|
| FY2021 | — | $217.8M | $144.9M |
| FY2022 | — | $184.8M | $113.6M |
| FY2023 | — | $159.6M | $191.4M |
| FY2024 | — | $229.0M | $128.0M |
| FY2025 | — | $352.5M | $84.2M |